The company said the patch is a potential solution for the 73% of migraine sufferers who experience nausea with their migraines.
Teva Pharmaceutical Industries on Monday announced that its acquistion of Labrys has been completed. The acquisition brings to Teva LBR-101, which is currently in phase-2b clinical trials for prevention of chronic and episodic migraines.
Endo International announced that its affiliates have acquired rights to Sumavel DosePro (sumatriptan injection) for subcutaneous use from Zogenix.
Dr. Reddy's Labs announced that it has launched Sumatriptan Injection USP, Autoinjector System 6-mg/0.5-mL, a generic version of Imitrex STATdose Pen (sumatriptan succinate) 6-mg/0.5-mL.
Teva Pharmaceutical announced that it has entered into a definitive agreement under which Teva will acquire NuPathe for $3.65 per share in cash.
Endo Health Solutions will acquire the maker of a patch used to treat migraines that received Food and Drug Administration approval at the beginning of this year.
Generic drug maker Par Pharmaceutical Cos. had sales of $227 million during fourth quarter 2010 and $1 billion for the year as a whole, according to an earnings statement Thursday.
US WorldMeds has announced a new treatment for migraines, the drug maker said Wednesday.
The Food and Drug Administration has approved a generic injected drug made by Sagent Pharmaceuticals...
A company that develops a drug for acute migraines in pill form that doesn’t interact...
Par Pharmaceutical Cos. had total sales of $291.9 million and $26.3 million in profit for...